AstraZeneca acquires SixPeaks Bio in USD 300 million transaction

"AstraZeneca has exercised an option to acquire SixPeaks Bio for a total consideration of USD 300 million (USD 170m upfront, USD 30m fixed, USD 100m contingent on regulatory milestones). Lenz & Staehelin represented AstraZeneca, while Walder Wyss advised SixPeaks Bio and its shareholders."

Lenz & Staehelin represented AstraZeneca, while Walder Wyss advised SixPeaks Bio and its shareholders. The transaction set a total consideration of USD 300 million. The reported amount comprises an upfront payment of USD 170 million, an additional fixed payment of USD 30 million and up to USD 100 million payable upon achievement of certain regulatory milestones. Lenz & Staehelin represented AstraZeneca with a team composed by: Tino Gaberthüel (M&A), who led the team, Raphael Fries (M&A), Nils Maag (M&A), Peter Ling (IP), Pascal Hinny (tax), Franziska Stadtherr-Glättli (tax), Anja Affolter Marino (employment) and Julia van Heusden (employment). Walder Wyss advised SixPeaks Bio and its shareholders with a team composed by: Partners Robert von Rosen (corporate/M&A) and Alexander Gutmans (corporate/M&A and venture capital), who led the team; managing associates Karina Tschon (corporate/M&A and venture capital) and Michelle Bruni (tax); senior associates Christoph Burckhardt (corporate/M&A) and Bojan Momic (corporate/M&A); and associates Oerjan Wickart (corporate/M&A) and Lorenzo Petrone (corporate/M&A).

AstraZeneca acquires SixPeaks Bio in USD 300 million transaction

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads